TuisMOLN • NASDAQ
add
Molecular Partners AG
Vorige sluiting
$3,56
Dagwisseling
$3,58 - $3,80
Jaarwisseling
$3,36 - $12,70
Markkapitalisasie
147,29 m USD
Gemiddelde volume
17,94 k
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CHF) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 16,14 m | 259,35% |
Netto inkomste | -16,77 m | -48,09% |
Netto winsgrens | — | — |
Wins per aandeel | -0,45 | — |
EBITDA | -15,59 m | -2,21% |
Effektiewe belastingkoers | 0,01% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CHF) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 130,91 m | -24,82% |
Totale bates | 141,10 m | -23,98% |
Totale aanspreeklikheid | 12,90 m | -24,36% |
Totale ekwiteit | 128,19 m | — |
Uitstaande aandele | 37,27 m | — |
Prys om te bespreek | 1,03 | — |
Opbrengs op bates | -26,94% | — |
Opbrengs op kapitaal | -29,41% | — |
Kontantvloei
Netto kontantverandering
| (CHF) | Mrt. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -16,77 m | -48,09% |
Kontant van bedrywe | -17,08 m | -0,18% |
Kontant van beleggings | 34,96 m | 98,53% |
Kontant van finansiering | -302,00 k | -0,67% |
Netto kontantverandering | 17,50 m | 1 588,90% |
Beskikbare kontantvloei | -13,72 m | -22,38% |
Meer oor
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Gestig
2004
Webwerf
Werknemers
159
